Hürthle 细胞癌 (HCC) 是滤泡型分化甲状腺癌 (DTC) 的一种不寻常且具有侵袭性的变体，占 DTC 的比例不到 3%，但转移风险最高。脑转移在文献中很少报道，但预后较差。 HCC 脑转移率低，加上颅外疾病的治疗方案不明确，使成功的疾病管理和明确的治疗策略变得复杂。作者介绍了一名 HCC 转移至颅底、皮质和脊柱且近期发生胫骨转移的患者的病例。尽管存在皮质、颅底和脊柱转移，但该患者对放射治疗、鞍区反应良好作者采用多学科方法对患者进行护理，其中包括来自肿瘤科、神经外科、骨科、放射科、内分泌科的多元化专家团队，并与临床试验研究人员合作，是她成功的基础，展示了交叉专业在神经肿瘤患者护理中取得成功结果的效用。

Hürthle cell carcinoma (HCC) is an unusual and aggressive variant of the follicular type of differentiated thyroid cancer (DTC), accounting for less than 3% of DTCs but posing the highest risk of metastasis. Brain metastases are uncommonly reported in the literature but pose a poor prognosis. The low rate of brain metastases from HCC coupled with ambiguous treatment protocols for the extracranial disease complicate successful disease management and definitive treatment strategy. The authors present the case of a patient with HCC metastasis to the skull base, cortex, and spine with recent tibial metastasis.Despite the presence of metastasis to the cortex, skull base, and spine, the patient responded very well to radiation therapy, sellar mass resection, and cervical spine decompression and fixation and has made a remarkable recovery.The authors' multidisciplinary approach to the patient's care, including a diverse team of specialists from oncology, neurosurgery, orthopedic surgery, radiology, endocrinology, and collaboration with clinical trial researchers, was fundamental to her successful outcome, demonstrating the utility of intersecting specialties in successful outcomes in neuro-oncological patient care.